CureVac Denies Takeover Reports As It Slates Phase I Coronavirus Vaccine Study For Early Summer
Executive Summary
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.
You may also be interested in...
Bright Wanted US To Purchase Of All Available Remdesivir Stock Early In Coronavirus Outbreak
The former BARDA director’s whistleblower complaint says he recommended the US government purchase all existing remdesivir doses and set up US-based manufacturing.
Drug Distributors Mitigate Coronavirus
For most patients, drug distributors – companies that provide, control and manage drug supplies – operate as an unseen but critical link in the supply chain. In the context of a global pandemic, however, drug distributors play an even bigger role in helping to ensure that pharmacies, health systems and ultimately patients have access to essential medicines.
Bharat, UW-Madison, FluGen Pursue Intranasal COVID-19 Vaccine
Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.